SCHEMBL4348781

SCHEMBL4348781

CCS(=O)(=O)c1ncc(C(=O)c2ccccc2C)c(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 8/20 0.48
CDK4 P11802 7/20 0.48
CCND1 P24385 7/20 0.48
CDK1 P06493 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 3/20 0.41
MAPT P10636 3/20 0.41
THRB P10828 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
ALDH1A1 P00352 3/20 0.41
CCNB2 O95067 1/20 0.40
CCNE2 O96020 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNE1 P24864 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
CCNA2 P20248 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348147 0.86 CDK2 (0.48) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4352671 0.84 CDK1 (0.56) CDK2CDK4CCND1CDK1NPC1
SCHEMBL4355765 0.84 CDK1 (0.52) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4350213 0.83 CDK4 (0.48) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4349180 0.79 CDK2 (0.51) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4350355 0.77 SMN1; SMN2 (0.53) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4350689 0.76 CDK4 (0.48) CDK2CDK4CCND1CDK1SMN1; SMN2
SCHEMBL4355723 0.73 CDK1 (0.55) CDK2CDK4CCND1CDK1TP53
SCHEMBL4357726 0.73 CDK1 (0.55) CDK2CDK4CCND1CDK1TP53
SCHEMBL14593697 0.72 CDK1 (0.45) CDK2CDK4CCND1CDK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
CN-101044121-A 4-aminopyrimidine-5-one HOFFMANN LA ROCHE (CH) 2007-09-26 CN disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK2 4/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK2 3/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.